GlobeNewswire·Jul 20, 2026, 7:00 AM ET

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

Kamada Ltd. announced a three-year agreement to supply normal source plasma to a leading biopharmaceutical company focused on plasma-derived therapies.
The supply agreement utilizes Kamada's collection centers in Texas and is expected to generate approximately $50 million in revenue over the three-year term.
Initial commercial sales under the agreement are projected to be recorded in the fourth quarter of 2026.
Kamada's FDA-approved plasma collection centers in Houston and San Antonio each support a planned capacity of approximately 50,000 liters per year at full capacity.
Expected fourth-quarter sales from this agreement are included in the Company's current annual guidance.
Kamada currently owns three FDA-approved operating plasma collection centers in Texas: Beaumont, Houston, and San Antonio.
FIMI Opportunity Funds is Kamada's controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.
The Company's strategy includes organic growth of six FDA-approved specialty plasma-derived products, distribution of third-party products in Israel & the MENA region, ramping up plasma collection operations, and pursuing new mergers & acquisitions.
Forward-looking statements in the release are subject to risks including geopolitical conflicts in the Middle East, tariff impacts on international trade, regulatory delays, & operational ramp-up efficiency.